Nuvectis Pharma FY2021 net loss $12.9M; IPO raised $16M; CFO replaced

Nuvectis Pharma, Inc.

Net loss of $12.9M for FY2021, including $7.0M upfront license payments and $1.9M non-cash equity compensation.
Cash and equivalents $5.7M at Dec 31, 2021; $16M gross IPO proceeds in Feb 2022 not included.
Phase 1a trial for NXP800 (HSF1 inhibitor) initiated Dec 2021; IND-enabling studies for NXP900 ongoing.
Michael Carson appointed VP of Finance, replacing interim CFO Uri Ben-Or; Carson is a CPA with biotech finance experience.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Carson

Vice President of Finance

NVCT · Nuvectis Pharma, Inc.

Effective: 2022-03-21
Filed: March 22, 2022, 7:59 PM ET

Michael Carson, who recently joined Nuvectis as Vice President of Finance, is replacing Uri Ben-Or

Departed (interim)

Uri Ben-Or

Interim Chief Financial Officer

NVCT · Nuvectis Pharma, Inc.

Effective: 2022-03-21
Successor: Michael Carson
Filed: March 22, 2022, 7:59 PM ET

Uri Ben-Or who served as the Company's Interim Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Carson was appointed as Vice President of Finance at Nuvectis Pharma, Inc..

Action: appointed
Role: Vice President of Finance

Exact text from the filing

Michael Carson, who recently joined Nuvectis as Vice President of Finance, is replacing Uri Ben-Or

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Uri Ben-Or departed as Interim Chief Financial Officer at Nuvectis Pharma, Inc..

Action: replaced
Role: Interim Chief Financial Officer

Exact text from the filing

Uri Ben-Or who served as the Company's Interim Chief Financial Officer.

View on SEC.gov

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-036359

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.